• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.

  • About
    • General Information
    • Disease Research
    • Education & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti-Aging Studies
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Tax Credit
    • Planned Giving
    • Vehicle Donations
    • Why We Give
    • Your Gift at Work
    • Donor Recognition
    • Contact
Home - OMRF News - Archives for Oblato

Oblato

Beating The Odds

Brain cancer survivor Mike Schuster celebrates a milestone he never thought possible.

OMRF brain tumor drug receives rare disease designations from the FDA

September 2, 2020

The drug treats fast-growing, deadly brain cancers with no effective treatment.

Filed Under: News, Technology Ventures News Tagged With: 007, administration, approval, bob, Bob Floyd, brain cancer, cancer, center, childhood, diffuse intrinsic pontine glioma, dipg, drug, FDA, Floyd, glioblastoma, glioma, Oblato, Oklahoma Medical Research Foundation, okn, OKN-007, OKN007, OMRF, OUHSC, pediatric, rare pediatric disease designation, Rheal, robert, rpdd, scientist-news, stephenson, Towner

Business of Health: Teaching an old drug new tricks

February 23, 2020

Typically, a promising new experimental drug arrives on the scene with a flourish. But sometimes, it’s a long and winding road.

Filed Under: On Your Health Tagged With: cerovise, company, drug, Floyd, korea, newsok, nhpn-1010, Oblato, Prescott, robert, steve, steven, therapy, treatment

Oblato acquires all rights to glioblastoma drug from OMRF

October 29, 2018

Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.

Filed Under: News, Technology Ventures News Tagged With: 007, americans, brain, cancer, clinical, deadly, diagnosis, drug, edward kennedy, Gtree, james battiste, john mccain, Manu Nair, mike schuster, model, news, Norman, Oblato, Oklahoma Medical Research Foundation, okn, OKN-007, OMRF, Rheal, rheal towner, robert floyd, scientist-news, Stephenson Cancer Center, technology, testing, therapy, Towner, treatment, trial, tumor, university of oklahoma

Biotech company acquires OMRF brain cancer drug

February 15, 2016

Agreement will expand clinical trials of glioblastoma drug

Filed Under: News Tagged With: brain cancer, brain tumor, cancer, clinical trial, glioblastoma, glioma, Gtree, GtreeBNT, investigational drug, Manu Nair, Oblato, OKN-007, pharmaceuticals, Rheal, scientist-news, Towner

Before Footer

EEO/AA Employer/Vet/Disabled

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayGive Smart OKCTop Workplace